Related Experiment Video

Updated: Jun 6, 2026

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

Global downstream pathway analysis reveals a dependence of oncogenic NF-E2-related factor 2 mutation on the mTOR

Tatsuhiro Shibata1, Shigeru Saito, Akiko Kokubu

  • 1Cancer Genomics Project and Pathology Division, National Cancer Center Research Institute, Tokyo, Japan. tashibat@ncc.go.jp

Cancer Research
|November 11, 2010
PubMed

Insights

Oncogenic NRF2 mutations drive cancer by activating the mTOR pathway, leading to increased cell growth and metastasis. Targeting NRF2 or the mTOR pathway offers a new strategy for cancer therapy and prognosis.

Area of Science:

  • Molecular Biology
  • Cancer Research
  • Cell Biology

Background:

  • NF-E2-related factor 2 (NRF2) regulates adaptive responses to oxidative stress and antioxidant genes.
  • Aberrant NRF2 activation is common in human cancers, but its precise role in cancer cells is not fully understood.

Purpose of the Study:

  • To investigate the biological consequences of NRF2 activation in cancer cells.
  • To explore the relationship between NRF2, the mammalian target of rapamycin (mTOR) pathway, and cancer progression.
  • To assess the therapeutic potential of targeting NRF2 or the mTOR pathway.

Main Methods:

  • Utilized genome-wide gene expression profiling to identify molecular pathways affected by mutant NRF2.
  • Investigated the role of RagD, a regulator of the mTOR pathway, in NRF2-driven cancers.
  • Tested the sensitivity of Nrf2-mutated cancer cells to mTOR pathway inhibitors in vitro and in vivo.
  • Analyzed gene expression signatures associated with mutant NRF2 as prognostic markers.

Main Results:

  • Mutant NRF2 promotes epithelial cell proliferation, anchorage-independent growth, tumorigenicity, and metastasis.
  • Mutant NRF2 upregulates RagD, activating the mTOR pathway, and this is observed in primary lung cancer.
  • Nrf2-mutated lung cancer cells are sensitive to mTOR inhibitors, demonstrating therapeutic vulnerability.
  • NRF2 mutation-associated gene expression signatures correlate with poor prognosis in head and neck and lung cancers.

Conclusions:

  • Oncogenic NRF2 mutations induce cancer cell dependence on the mTOR pathway.
  • Targeting NRF2 presents a potential anticancer strategy.
  • NRF2 activation serves as a novel biomarker for personalized therapy and prognostic assessment.

More Related Videos

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...